2. Search Result
Search Result
Results for "

RPMI-8226

" in MedChemExpress (MCE) Product Catalog:

29

Inhibitors & Agonists

1

Biochemical Assay Reagents

1

Inhibitory Antibodies

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-145564
    Emprumapimod

    PF-07265803

    		 p38 MAPK Cardiovascular Disease Inflammation/Immunology
    Emprumapimod (PF-07265803) is a potent, orally active and selective inhibitor of p38α MAPK directly inhibits LPS-induced IL-6 production from RPMI-8226 cell (IC50=100 pM). Emprumapimod can be used for the research of dilated cardiomyopathy and acute inflammatory pain .
    Emprumapimod
  • HY-164099
    LSD1/HDAC6-IN-2

    		HDAC Monoamine Oxidase Histone Demethylase Cancer
    LSD1/HDAC6-IN-2 (JBI-802) is an orally active LSD1/HDAC6/MAO-A inhibitor, with IC50 values of 5 nM, 11 nM, and 5 nM, respectively. LSD1/HDAC6-IN-2 can inhibit the growth of multiple myeloma cells MM.1S, MM.1R, and RPMI-8226. LSD1/HDAC6-IN-2 can be used for research on diseases such as acute myeloid leukemia and lymphoma .
    LSD1/HDAC6-IN-2
  • HY-10455
    Carfilzomib
    Maximum Cited Publications
    43 Publications Verification

    PR-171

    		 Proteasome Autophagy Apoptosis Cancer
    Carfilzomib (PR-171) is an irreversible proteasome inhibitor with an IC50 of 5 nM in ANBL-6 and RPMI 8226 cells.
    Carfilzomib
  • HY-10455S
    Carfilzomib-d8

    		Isotope-Labeled Compounds Proteasome Autophagy Apoptosis Cancer
    Carfilzomib-d8 is deuterium labeled Carfilzomib. Carfilzomib (PR-171) is an irreversible proteasome inhibitor with an IC50 of 5 nM in ANBL-6 and RPMI 8226 cells.
    Carfilzomib-d8
  • HY-104040
    MKC8866
    10+ Cited Publications

    Orin1001

    		 IRE1 Cancer
    MKC8866, a salicylaldehyde analog, is a potent, selective IRE1 RNase inhibitor with an IC50 of 0.29 μM in human vitro. MKC8866 strongly inhibits Dithiothreitol-induced X-box-binding protein 1-spliced (XBP1s) expression with an EC50 of 0.52 μM and unstresses RPMI 8226 cells with an IC50 of 0.14 μM . MKC8866 inhibits IRE1 RNase in breast cancer cells leading to the decreased production of pro-tumorigenic factors and it can inhibits prostate cancer (PCa) tumor growth .
    MKC8866
  • HY-149832
    Anticancer agent 114

    		Proteasome Cancer
    Anticancer agent 114 is a potent and orally active dipeptide boronic acid ester proteasome inhibitor with an IC50 value of 2.2 nM. Anticancer agent 114 has antiproliferative activity against the RPMI-8226 cells. Anticancer agent 114 can be used in research of multiple myeloma .
    Anticancer agent 114
  • HY-144369
    Proteasome-IN-4

    		Proteasome Cancer
    Proteasome-IN-4 is an excellent and non-covalent proteasome inhibitor (IC50=8.39 nM). Proteasome-IN-4 has potent antiproliferative activities against RPMI-8226, MM-1S and MV-4-11 cell lines. Proteasome-IN-4 can be used for cancer research .
    Proteasome-IN-4
  • HY-P991462
    GBR-1342

    		CD38 Cancer
    GBR-1342 is a human bispecific antibody (bsAb) targeting CD38 & CD3. GBR-1342 inhibits the activity of Daudi, RAJI, RPMI8226, IM-9, and NCI-H929 cancer cell lines. GBR-1342 can be used in myeloma research .
    GBR-1342
  • HY-10455R
    Carfilzomib (Standard)

    PR-171 (Standard)

    		 Reference Standards Proteasome Autophagy Apoptosis Cancer
    Carfilzomib (Standard) is the analytical standard of Carfilzomib. This product is intended for research and analytical applications. Carfilzomib (PR-171) is an irreversible proteasome inhibitor with an IC50 of 5 nM in ANBL-6 and RPMI 8226 cells.
    Carfilzomib (Standard)
  • HY-155231
    Neutrophil elastase inhibitor 4

    		Elastase Cancer
    Neutrophil elastase inhibitor 4 (compound 4f) is a competitive human neutrophil elastase (HNE) inhibitor (IC50: 42.30 nM, Ki: 8.04 nM). Neutrophil elastase inhibitor 4 induces T47D cell apoptosis. Neutrophil elastase inhibitor 4 inhibits cell proliferation with IC50s of 21.25, 34.17, 29.93, 99.11 nM for T47D, RPMI 8226, A549, and HSF cells .
    Neutrophil elastase inhibitor 4
  • HY-168338
    CB2 receptor agonist 8

    		Cannabinoid Receptor Caspase Cancer
    CB2 receptor agonist 8 (Compound 17) is an agonist for cannabinoid receptor 2 (CB2 receptor). CB2 receptor agonist 8 exhibits cytotoxicity in cells U87, RPMI 8226, HL-60, and L929 with IC50s of 91.03, 16.29, 23.51 and 564.6 μM, respectively. CB2 receptor agonist 8 activates caspase 3/7, increases the expressions of pro-apoptotic genes BAX, BAD, BIM and tumor suppressor genes p53, and induces apoptosis in U87. CB2 receptor agonist 8 inhibits the migration of U87 .
    CB2 receptor agonist 8
  • HY-168326
    Antiproliferative agent-64

    		DNA/RNA Synthesis Microtubule/Tubulin Cancer
    Antiproliferative agent-64 (Compound 76) is an inhibitor for eukaryotic translation initiation factor 4E (eIF4E), that block the secondary structure of mRNA, thereby inhibiting protein translation. Antiproliferative agent-64 inhibits the 5' untranslated region (5'UTR) of c-Myc (c-myc 5'UTR) with an EC50 of 1.2 nM, inhibits 5'UTR encoding tubulin (tub 5'UTR) with an EC50 of 40 nM. Antiproliferative agent-64 inhibits the proliferation of MDA-MB-231 with an EC50 of 7 nM .
    Antiproliferative agent-64
  • HY-149896
    Antitumor agent-107

    		Biochemical Assay Reagents Cancer
    Antitumor agent-107 (compound 5h) is an anticancer agent that shows excellent inhibitory activity against leukemia cell lines (GI50=0.32-1.34 μM). Antitumor agent-107 also shows antitumor activity against various other human cancer cell lines (GI50 range 0.35-9.43 μM) .
    Antitumor agent-107
  • HY-150595
    HDAC6-IN-10

    		HDAC Microtubule/Tubulin Cancer
    HDAC6-IN-10 is a highly selective HDAC6 inhibitor with the IC50 of 0.73 nM. HDAC6-IN-10 has 144~10941-fold selectivity over other HDAC isoforms. HDAC6-IN-10 shows anti-proliferative activities against multiple myeloma cells .
    HDAC6-IN-10
  • HY-168994
    DfrA1-IN-1

    		Bacterial Infection
    DfrA1-IN-1 (Compound DC6) is an orally active DfrA1 inhibitor with strong binding ability to DfrA1. DfrA1-IN-1 can be used in research related to trimethoprim-resistant bacterial infections .
    DfrA1-IN-1
  • HY-163409
    CGK012

    		Wnt β-catenin Inflammation/Immunology Cancer
    CKG012 is an inhibitor for Wnt/βcatenin signaling pathway. CGK012 inhibits release of HMGB1 and transcription of β-catenin, exhibits attenuating activities against cecal ligation and puncture (CLP)-induced sepsis and multiple myeloma cancer .
    CGK012
  • HY-156279
    HDAC6-IN-22

    		Apoptosis HDAC Cancer
    HDAC6-IN-22 (compound 30) is a inhibitor of HDAC6, with the IC50 of 4.63 nM. HDAC6-IN-22 has antiproliferative effects in vitro and in vivo towards multiple myeloma. HDAC6-IN-22 induces cell cycle arrest in the G2 phase and promotes apoptosis through the mitochondrial pathway .
    HDAC6-IN-22
  • HY-161967
    JAK2/FLT3-IN-3

    		FLT3 JAK Apoptosis Cancer
    JAK2/FLT3-IN-3 (11r) is a dual FLT3 and JAK2 inhibitor, with IC50 values of 2.01 nM, 0.51 nM and 104.40 nM for JAK2, FLT3 and JAK3, respectively. JAK2/FLT3-IN-3 (11r) induces apoptosis and possesses antitumor activity .
    JAK2/FLT3-IN-3
  • HY-168902
    Proteasome-IN-7

    		Proteasome Cancer
    Proteasome-IN-7 (Compound 6f) is an epoxyketone macrocyclic peptidyl proteasome inhibitor (IC50 value of 37.92 nM for 20S proteasome ChT-L subunit). Proteasome-IN-7 displays robust antiproliferative effects against multiple myeloma, acute lymphoblastic leukemia and non-small cell lung cancer .
    Proteasome-IN-7
  • HY-B0812
    5-Sulfosalicylic acid dihydrate
    1 Publications Verification

    SSA dihydrate

    		 Biochemical Assay Reagents Cancer
    5-Sulfosalicylic acid dihydrate is a sulfonated salicylic acid derivative. 5-Sulfosalicylic acid dihydrate is effective against the breast cancer cell line, MCF-7, with less toxicity . 5-Sulfosalicylic acid dihydrate has antioxidant activities .
    5-Sulfosalicylic acid dihydrate
  • HY-149513
    EP12

    		c-Myc Apoptosis Cancer
    EP12 is a c-Myc inhibitor. EP12 is a c-Myc G4 stabilizer. EP12 induces apoptosis and DNA damage in multiple myeloma cells. EP12 disrupts the nuclear translocation of P65/P50 by interfering with the NF-κB signaling pathway. EP12 inhibits multiple myeloma growth .
    EP12
  • HY-15728
    Radotinib

    IY-5511

    		 Bcr-Abl Apoptosis STAT JAK Prion Protein Infection Neurological Disease Cancer
    Radotinib (IY-5511) is an orally active and BBB-permeable selective tyrosine kinase Bcr-Abl1 inhibitor with an IC50 of 34 nM. Radotinib has anti-prion and anti-tumor activities. Radotinib can inhibit the proliferation, induce cell cycle arrest and apoptosis of tumor cells . Radotinib can be used in the research of cancer such as chronic myeloid leukemia and multiple myeloma, as well as neurodegenerative diseases such as prion diseases .
    Radotinib
  • HY-116392D
    PDMP hydrochloride

    		Glucosylceramide Synthase (GCS) Apoptosis Cancer
    PDMP hydrochloride is a glucosylceramide synthase (GCS) inhibitor. PDMP hydrochloride induces apoptosis in K562/A02 cells. PDMP hydrochloride can be used in cancer (such as leukemia) research .
    PDMP hydrochloride
  • HY-146444
    Anticancer agent 56

    		Apoptosis Bcl-2 Family Caspase Reactive Oxygen Species (ROS) Cancer
    Anticancer agent 56 (compound 4d) is a potent anti-cancer agent with agent-likeness properties, possessing anticancer activity against several cancer cell lines (IC50<3 μM). Anticancer agent 56 induces cell cycle arrest at G2/M phase and triggers mitochondrial apoptosis pathway. Anticancer agent 56 acts by accumulation of ROS, up regulation of BAX, down regulation of Bcl-2 and activation of caspases 3, 7, 9 .
    Anticancer agent 56
  • HY-19322B
    PIM-447 dihydrochloride
    5+ Cited Publications

    LGH447 dihydrochloride

    		 Pim Apoptosis Cancer
    PIM447 dihydrochloride (LGH447 dihydrochloride) is a potent, orally available, and selective pan-PIM kinase inhibitor, with Ki values of 6, 18, and 9 pM for PIM1, PIM2, and PIM3, respectively. PIM447 dihydrochloride displays dual antimyeloma and bone-protective effects. PIM447 dihydrochloride induces apoptosis .
    PIM-447 dihydrochloride
  • HY-174445
    C199

    		PROTACs Histone Methyltransferase Apoptosis Cancer
    C199 is a PROTAC degrader targeting PRMT4 (DC50 = 106 nM). C199 shows high selectivity for PRMT4 over other protein arginile methyltransferases. C199 exhibits strong cell degradation ability. C199 induces apoptosis in MM cell lines. C199 efficiently clears PRMT4 protein via the VHL-proteasome pathway. C199 has a relatively long half-life and shows strong anti-multiple myeloma (MM) tumor activity (Pink: Target protein ligand (HY-111109); Blue: E3 ligase ligand (HY-112078), E3 ligase ligand + linker (HY-174474); black: Linker) .
    C199
  • HY-115993
    CDK4/6-IN-10

    		CDK Apoptosis Cancer
    CDK4/6-IN-10 is a potent, selective and orally active CDK4 and CDK6 inhibitor with IC50s of 22 nM and 10 nM, respectively. CDK4/6-IN-10 shows antitumor activity. CDK4/6-IN-10 has the potential for the research of Multiple myeloma (MM) .
    CDK4/6-IN-10
  • HY-148369
    U7D-1

    		PROTACs Deubiquitinase Apoptosis MDM-2/p53 Cancer
    U7D-1 is a first-in-class potent and selective USP7 (ubiquitin-specific protease 7) PROTAC degrader, with a DC50 of 33 nM in RS4;11 cells. U7D-1 shows anticancer activity. U7D-1 induces apoptosis in Jeko-1 cells .
    U7D-1
  • HY-169021
    JNK-1-IN-3

    		JNK Cancer
    JNK-1-IN-3 (Compound 9e) is an inhibitor of JNK1 that downregulates JNK1 gene expression and inhibits the protein levels of its phosphorylated form, concurrently reducing the expression of its downstream targets, c-Jun and c-Fos, in tumors while restoring p53 activity. JNK-1-IN-3 exhibits broad-spectrum antiproliferative activity, particularly with high inhibitory activity against renal and breast cancer cell lines, demonstrating both in vivo and in vitro anticancer activity .
    JNK-1-IN-3

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: